Top

BMC Cancer

Published in:

Open Access 01-12-2012 | Research article

A closed-tube methylation-sensitive high resolution melting assay (MS-HRMA) for the semi-quantitative determination of CST6 promoter methylation in clinical samples

Authors: Lampros Dimitrakopoulos, Panagiotis A Vorkas, Vasilis Georgoulias, Evi S Lianidou

Published in: BMC Cancer | Issue 1/2012

Abstract

Background

CST6 promoter is highly methylated in cancer, and its detection can provide important prognostic information in breast cancer patients. The aim of our study was to develop a Methylation-Sensitive High Resolution Melting Analysis (MS-HRMA) assay for the investigation of CST6 promoter methylation.

Methods

We designed primers that amplify both methylated and unmethylated CST6 sequences after sodium bisulfate (SB) treatment and used spiked control samples of fully methylated to unmethylated SB converted genomic DNA to optimize the assay. We first evaluated the assay by analyzing 36 samples (pilot training group) and further analyzed 80 FFPES from operable breast cancer patients (independent group). MS-HRMA assay results for all 116 samples were compared with Methylation-Specific PCR (MSP) and the results were comparable.

Results

The developed assay is highly specific and sensitive since it can detect the presence of 1% methylated CST6 sequence and provides additionally a semi-quantitative estimation of CST6 promoter methylation. CST6 promoter was methylated in 39/80 (48.75%) of FFPEs with methylation levels being very different among samples. MS-HRMA and MSP gave comparable results when all samples were analyzed by both assays.

Conclusions

The developed MS-HRMA assay for CST6 promoter methylation is closed tube, highly sensitive, cost-effective, rapid and easy-to-perform. It gives comparable results to MSP in less time, while it offers the advantage of additionally providing an estimation of the level of methylation.

Available only for authorised users

Laird PW: The power and promise of DNA methylation markers. Nat Rev Cancer. 2003, 3: 253-266. 10.1038/nrc1045.CrossRefPubMed

Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR, Sukumar S: High frequency of hypermethylation at the 14.3.3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA. 2000, 97: 6049-6054. 10.1073/pnas.100566997.CrossRefPubMedPubMedCentral

Esteller M: Epigenetics in cancer (Review). N Engl J Med. 2008, 358: 1148-1159. 10.1056/NEJMra072067.CrossRefPubMed

Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002, 3: 415-428.CrossRefPubMed

Esteller M: CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002, 21: 5427-5440. 10.1038/sj.onc.1205600.CrossRefPubMed

Wojdacz TK, Dobrovic A, Hansen LL: Methylation-sensitive high-resolution melting. Nat Protoc. 2008, 3: 1903-1908. 10.1038/nprot.2008.191.CrossRefPubMed

Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, Pryor RJ: High-Resolution Genotyping by Amplicon Melting Analysis Using LCGreen. Clin Chem. 2003, 49: 853-860. 10.1373/49.6.853.CrossRefPubMed

Reed GH, Wittwer CT: Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis. Clin Chem. 2004, 50: 1748-1754. 10.1373/clinchem.2003.029751.CrossRefPubMed

Liew M, Pryor R, Palais R, Meadows C, Erali M, Lyon E, Wittwer C: Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. Clin Chem. 2004, 50: 1156-1164. 10.1373/clinchem.2004.032136.CrossRefPubMed

10.

Gundry CN, Dobrowolski SF, Martin YR, Robbins TC, Nay LM, Boyd N: Base-pair neutral homozygotes can be discriminated by calibrated high-resolution melting of small amplicons. Nucleic Acids Res. 2008, 36: 3401-3408. 10.1093/nar/gkn204.CrossRefPubMedPubMedCentral

11.

Krypuy M, Newnham GM, Thomas DM, Conron M, Dobrovic A: High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer. 2006, 6: 295-10.1186/1471-2407-6-295.CrossRefPubMedPubMedCentral

12.

Zhou L, Wang Y, Wittwer CT: Rare allele enrichment and detection by allele-specific PCR, competitive probe blocking and melting analysis. Biotechniques. 2011, 50: 311-318.

13.

Wojdacz TK, Dobrovic A: Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res. 2007, 35: e41-10.1093/nar/gkm013.CrossRefPubMedPubMedCentral

14.

Turk V, Bode W: The cystatins: protein inhibitors of cystein proteininases. FEBS Lett. 1991, 285: 213-219. 10.1016/0014-5793(91)80804-C.CrossRefPubMed

15.

Sotiropoulou G, Anisowicz A, Sager R: Identification, cloning, and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer. J Biol Chem. 1997, 272: 903-910. 10.1074/jbc.272.2.903.CrossRefPubMed

16.

Ni J, Abrahamson M, Zhang M, Fernandez MA, Grubb A, Su J, Yu GL, Li Y, Parmelee D, Xing L, Coleman TA, Gentz S, Thotakura R, Nguyen N, Hesselberg M, Gentz R: Cystatin E is a novel human cysteine proteinase inhibitor with structural resemblance to family 2 cystatins. J Biol Chem. 1997, 272: 10853-10858. 10.1074/jbc.272.16.10853.CrossRefPubMed

17.

Stenman G, Astrom AK, Roijer E, Sotiropoulou G, Zhang M, Sager R: Assignment of a novel cysteine proteinase inhibitor (CST6) to 11q13 by fluorescence in situ hybridization. Cytogenet Cell Gent. 1997, 76: 45-46. 10.1159/000134512.CrossRef

18.

Zeeuwen PL, Cheng T, Schalkwijk J: The biology of cystatin M/E and its cognate target proteases. J Invest Dermatol. 2009, 129: 1327-1338. 10.1038/jid.2009.40.CrossRefPubMed

19.

Cheng T, Hitomi K, van Vlijmen-Willems IM, de Jongh GJ, Yamamoto K, Nishi K, Watts C, Reinheckel T, Schalkwijk J, Zeeuwen PL: Cystatin M/E is a high affinity inhibitor of cathepsin V and cathepsin L by a reactive site that is distinct from the legumain-binding site. A novel clue for the role of cystatin M/E in epidermal cornification. J Biol Chem. 2006, 281: 15893-15899. 10.1074/jbc.M600694200.CrossRefPubMed

20.

Gawenda J, Traub F, Lück HJ, Kreipe H, von Wasielewski R: Legumain expression as a prognostic factor in breast cancer patients. Breast Cancer Res Treat. 2007, 102: 1-6. 10.1007/s10549-006-9311-z.CrossRefPubMed

21.

Murthy RV, Arbman G, Gao J, Roodman GD, Sun XF: Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin Cancer Res. 2005, 11: 2293-2299. 10.1158/1078-0432.CCR-04-1642.CrossRefPubMed

22.

Mohamed MM, Sloane BF: Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer. 2006, 6: 764-775. 10.1038/nrc1949.CrossRefPubMed

23.

Ai L, Kim W, Kim TY, Fields CR, Massoll NA, Robertson KD, Brown KD: Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. Cancer Res. 2006, 66: 7899-7909. 10.1158/0008-5472.CAN-06-0576.CrossRefPubMed

24.

Rivenbark AG, Jones WD, Coleman WB: DNA methylation-dependent silencing of CST6 in human breast cancer cell lines. Lab Invest. 2006, 86: 1233-1242. 10.1038/labinvest.3700485.CrossRefPubMed

25.

Schagdarsurengin U, Pfeifer GP, Dammann R: Frequent epigenetic inactivation of cystatin M in breast carcinoma. Oncogene. 2007, 26: 3089-3094. 10.1038/sj.onc.1210107.CrossRefPubMed

26.

Kioulafa M, Balkouranidou I, Sotiropoulou G, Kaklamanis L, Mavroudis D, Georgoulias V, Lianidou ES: Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer. Int J Cancer. 2009, 125: 2887-2892. 10.1002/ijc.24686.CrossRefPubMed

27.

Chimonidou M, Strati A, Tzitzira A, Sotiropoulou G, Malamos N, Georgoulias V, Lianidou ES: DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Clin Chem. 2011, 57: 1169-1177. 10.1373/clinchem.2011.165902.CrossRefPubMed

28.

Kroupis C, Christopoulos K, Devetzoglou M, Tsiagas I, Lianidou ES: Asymmetric real-time PCR detection of BRCA1 5382insC mutation by melting curve analysis in the LightCycler. Clin Chim Acta. 2008, 390: 141-144. 10.1016/j.cca.2007.12.024.CrossRefPubMed

29.

Warnecke PM, Stirzaker C, Melki JR, Millar DS, Paul CL, Clark SJ: Detection and measurement of PCR bias in quantitative methylation analysis of bisulphate-treated DNA. Nucleic Acids Res. 1997, 25: 4422-4426. 10.1093/nar/25.21.4422.CrossRefPubMedPubMedCentral

30.

Wojdacz TK, Borgbo T, Hansen LL: Primer design versus PCR bias in methylation independent PCR amplifications. Epigenetics. 2009, 4 (4): 231-234.CrossRefPubMed

31.

Wojdacz TK, Dobrovic A: Melting curve assays for DNA methylation analysis. Methods Mol Biol. 2009, 507: 229-240. 10.1007/978-1-59745-522-0_17.CrossRefPubMed

32.

Wojdacz TK, Hansen LL, Dobrovic A: A new approach to primer design for the control of PCR bias in methylation studies. BMC Res Notes. 2008, 1: 54-10.1186/1756-0500-1-54.CrossRefPubMedPubMedCentral

33.

Wojdacz TK, Hansen LL: Reversal of PCR bias for improved sensitivity of the DNA methylation melting curve assay. Biotechniques. 2006, 41: 274, 276-278.CrossRef

34.

Rivenbark AG, Livasy CA, Boyd CE, Keppler D, Coleman WB: Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions. Exp Mol Pathol. 2007, 83: 188-197. 10.1016/j.yexmp.2007.03.008.CrossRefPubMedPubMedCentral

35.

Kundel HL, Polansky M: Measurement of observer agreement. Radiology. 2003, 228: 303-308. 10.1148/radiol.2282011860.CrossRefPubMed

36.

Qiu J, Ai L, Ramachandran C, Yao B, Gopalakrishnan S, Fields CR, Delmas AL, Dyer LM, Melnick SJ, Yachnis AT, Schwartz PH, Fine HA, Brown KD, Robertson KD: Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas. Lab Invest. 2008, 88: 910-925. 10.1038/labinvest.2008.66.CrossRefPubMedPubMedCentral

37.

Veena MS, Lee G, Keppler D, Mendonca MS, Redpath JL, Stanbridge EJ, Wilczynski SP, Srivatsan ES: Inactivation of the cystatin E/M tumor suppressor gene in cervical cancer. Genes Chromosomes Cancer. 2008, 47: 740-754. 10.1002/gcc.20576.CrossRefPubMedPubMedCentral

38.

Pulukuri SM, Gorantla B, Knost JA, Rao JS: Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer. Oncogene. 2009, 28: 2829-2838. 10.1038/onc.2009.134.CrossRefPubMedPubMedCentral

39.

Lin HJ, et al: Breast cancer-associated fibroblasts confer AKT1-mediated epigenetic silencing of Cystatin M in epithelial cells. Cancer Res. 2008, 68: 10257-10266. 10.1158/0008-5472.CAN-08-0288.CrossRefPubMedPubMedCentral

40.

Radpour R, Kohler C, Haghighi MM, Fan AX, Holzgreve W, Zhong XY: Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array. Oncogene. 2009, 28: 2969-2978. 10.1038/onc.2009.149.CrossRefPubMed

41.

Rodenhiser DI, Andrews J, Kennette W, Sadikovic B, Mendlowitz A, Tuck AB, Chambers AF: Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays. Breast Cancer Res. 2008, 10: R62-10.1186/bcr2121.CrossRefPubMedPubMedCentral

42.

Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N, Brown M, Kishida T, Yao M, Latif F, Maher ER: Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene. 2010, 29: 2104-2117. 10.1038/onc.2009.493.CrossRefPubMedPubMedCentral

43.

Ko E, Park SE, Cho EY, Kim Y, Hwang JA, Lee YS, Nam SJ, Bang S, Park J, Kim DH: Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer. Breast Cancer Res. 2010, 12: R100-10.1186/bcr2783.CrossRefPubMedPubMedCentral

44.

Dahl C, Guldberg P: High-Resolution Melting for Accurate Assessment of DNA Methylation. Clin Chem (editorial). 2007, 53: 1877-1878. 10.1373/clinchem.2007.094854.CrossRef

45.

Worm J, Aggerholm A, Guldberg P: In-tube DNA methylation profiling by fluorescence melting curve analysis. Clin Chem. 2001, 47: 1183-1189.PubMed

46.

Guldberg P, Worm J, Grønbæk K: Profiling DNA methylation by melting analysis. Methods. 2002, 27: 121-127. 10.1016/S1046-2023(02)00063-4.CrossRefPubMed

47.

Dahl C, Grønskov K, Larsen LA, Guldberg P, Brøndum-Nielsen K: A homogeneous assay for analysis of FMR1 promoter methylation in patients with fragile X syndrome. Clin Chem. 2007, 53: 790-793. 10.1373/clinchem.2006.080762.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/486/prepub

Title: A closed-tube methylation-sensitive high resolution melting assay (MS-HRMA) for the semi-quantitative determination of CST6 promoter methylation in clinical samples
Authors: Lampros Dimitrakopoulos
Panagiotis A Vorkas
Vasilis Georgoulias
Evi S Lianidou
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-12-486

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Interaction between interleukin-10 (IL-10) polymorphisms and dietary fibre in relation to risk of colorectal cancer in a Danish case-cohort study

Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model

DNA methylation regulates expression of VEGF-R2 (KDR) and VEGF-R3 (FLT4)

Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation

Expression profile and prognostic role of sex hormone receptors in gastric cancer

Characterization of human gastric carcinoma-related methylation of 9 miR CpG islands and repression of their expressions in vitro and in vivo

Keynote webinar | Spotlight on antibody–drug conjugates in cancer